Markets:

Overview

News

Currencies

International

Treasuries

Personalis, Inc. - Common Stock (NQ:PSNL)

6.600 -0.720 (-9.84%)

Streaming Delayed Price Updated: 12:48 PM EDT, Mar 27, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Personalis, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 Next >

Personalis to Announce Third Quarter 2023 Financial Results

October 24, 2023

From Personalis, Inc.

Via Business Wire

Analysis from TRACERx Study Reveals More Sensitive and Earlier ctDNA Detection in Lung Cancer Patients by Personalis' MRD Technology

October 21, 2023

From Personalis, Inc.

Via Business Wire

Personalis Announces Late-Breaking NeXT Personal Abstract and Proffered Paper Presentation at ESMO 2023

October 19, 2023

From Personalis, Inc.

Via Business Wire

Analyst Ratings for Personalis ↗

May 04, 2023

Via Benzinga

Recap: Personalis Q1 Earnings ↗

May 03, 2023

Via Benzinga

Personalis's Return On Capital Employed Insights ↗

February 28, 2023

Via Benzinga

Earnings Outlook For Personalis ↗

February 22, 2023

Via Benzinga

Personalis Appoints Former Roche Diagnostics and GRAIL Executive Deepshikha Bhandari as SVP, Regulatory, Quality and Clinical Compliance

October 18, 2023

From Personalis, Inc.

Via Business Wire

Stocks That Hit 52-Week Lows On Friday ↗

September 29, 2023

Friday's session saw 112 companies set new 52-week lows.

Via Benzinga

Stocks That Hit 52-Week Lows On Friday ↗

September 15, 2023

Friday's session saw 169 companies set new 52-week lows.

Via Benzinga

Personalis to Present at the 21st Annual Morgan Stanley Global Healthcare Conference

August 29, 2023

From Personalis, Inc.

Via Business Wire

Personalis Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

August 24, 2023

From Personalis, Inc.

Via Business Wire

Personalis Reports Second Quarter 2023 Financial Results

August 08, 2023

From Personalis, Inc.

Via Business Wire

Personalis to Participate at Upcoming Investor Conferences

August 01, 2023

From Personalis, Inc.

Via Business Wire

Personalis to Announce Second Quarter 2023 Financial Results

July 25, 2023

From Personalis, Inc.

Via Business Wire

Personalis Files Second Patent Infringement Suit Against Foresight Diagnostics

June 26, 2023

From Personalis, Inc.

Via Business Wire

Dr. Kenneth J. Widder Joins Personalis Board of Directors

June 13, 2023

From Personalis, Inc.

Via Business Wire

Personalis Announces Two Abstracts Accepted for Presentation at ASCO 2023

May 30, 2023

From Personalis, Inc.

Via Business Wire

Personalis, National Cancer Center Hospital East, and Ono Collaborate to Better Predict Immunotherapy Response for Rectal Cancer

May 16, 2023

From Personalis, Inc.

Via Business Wire

Personalis Reports First Quarter 2023 Financial Results

May 03, 2023

From Personalis, Inc.

Via Business Wire

Personalis, ABRCC, and Criterium Announce Major Prospective Clinical Trial for Residual and Recurrent Disease Detection in Triple Negative Breast Cancer

May 02, 2023

From Personalis, Inc.

Via Business Wire

Personalis to Announce First Quarter 2023 Financial Results

April 19, 2023

From Personalis, Inc.

Via Business Wire

Personalis to Participate at the 22nd Annual Needham Virtual Healthcare Conference

April 05, 2023

From Personalis, Inc.

Via Business Wire

Personalis Joins Top UK Cancer Research Organizations to Evaluate Earlier Cancer Recurrence Detection Through Groundbreaking Study

April 05, 2023

From Personalis, Inc.

Via Business Wire

Personalis Announces Four Abstracts Accepted for Presentation at AACR Annual Meeting 2023

March 22, 2023

From Personalis, Inc.

Via Business Wire

Personalis Selected for Clinical Research After Successful Evaluation of Whole Genome-Based Molecular Residual Disease Assay

March 07, 2023

From Personalis, Inc.

Via Business Wire

Personalis Appoints Christopher Hall as Chief Executive Officer

March 02, 2023

From Personalis, Inc.

Via Business Wire

Toll Brothers To Rally 25%? Here Are 10 Other Analyst Forecasts For Friday ↗

February 24, 2023

Oppenheimer boosted the price target for Universal Display Corporation (NASDAQ: OLED) from $150 to $160. Oppenheimer analyst Martin Yang maintained an Outperform rating on the stock. Universal Display...

Via Benzinga

Personalis Reports Fourth Quarter and Full Year 2022 Financial Results

February 23, 2023

From Personalis, Inc.

Via Business Wire

Earnings Scheduled For February 23, 2023 ↗

February 23, 2023

Companies Reporting Before The Bell • ChipMOS TECHNOLOGIES (NASDAQ:IMOS) is likely to report earnings for its fourth quarter.

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 9 10 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.